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We reviewed the literature for cases in which gynecologic malignancies caused paraneoplastic retinopathy and ultimately led to
blindness. Twenty-eight cases were derived from the literature, and one unique case is described from our institution. Of these 28
cases, 14 patients were diagnosed with endometrial cancer, 7 with ovarian cancer, 5 with cervical cancer, 1 fallopian tube cancer
and 1 with concomitant endometrial and ovarian cancers. The average age of patients at the time of diagnosis was 64 years (range,
35–89 years). Typically, ocular manifestations antedate symptoms of the underlying carcinoma by 3–12 months. Information
regarding the interval from visual symptoms to time of death is limited, but ranges from several months to several years. Our
report is the ﬁrst to document a clear cell carcinoma of the endometrium causing paraneoplastic retinopathy and is the ﬁrst to
review all gynecologic malignancies associated with visual paraneoplastic syndromes.
1.Introduction
Paraneoplasticsyndromesarecharacterizedbyremoteeﬀects
of a cancer that occur at sites distant from the primary
tumor or its metastases. Visual paraneoplastic syndromes
are rare and are thought to be mediated by an autoimmune
process [1]. Corticosteroids and plasmapheresis are the only
treatment options previously described. We review the lit-
erature of gynecologic cancers causing visual paraneoplastic
syndromes and report the ﬁrst case of clear cell carcinoma of
the endometrium causing paraneoplastic retinopathy.
2.CaseReport
A 62-year-old woman presented with a 1-year history
of postmenopausal bleeding. Preoperative MRI revealed
less than 50% myometrial invasion, and she was treated
surgically at an aﬃliated hospital with a total abdominal
hysterectomy and left salpingo-oophorectomy. She had pre-
viously undergone a right salpingo-oophorectomy. The ﬁnal
pathology revealed a stage 3 clear cell carcinoma with disease
penetration to the level of the serosa. Postoperative imaging
revealed pelvic and para-aortic lymphadenopathy, and, after
discussion at our multidisciplinary rounds, the decision
w a sm a d et ot a k eh e rb a c kt ot h eo p e r a t i n gr o o mf o ra
systematic lymphadenectomy with the hopes of “debulking”
and tailoring adjuvant radiation treatment.
She underwent a robotic assisted pelvic and para-
aortic lymphadenectomy from which all thirty lymph nodes
removed were found to be negative. After her procedure, due
to her high-risk features, she received adjuvant chemother-
apy with carboplatin and paclitaxel. The intention was that
she receives 6 cycles of chemotherapy followed by pelvic and
para-aortic radiation. Unfortunately, she displayed ongoing
f a t i g u ea n dh a dad r o pi nh e m o g l o b i na v e r a g i n g2 0 g m / L
witheachtreatmentresultinginredbloodcelltransfusionon2 Case Reports in Obstetrics and Gynecology
Table 1: Reported gynecologic cancers associated with paraneoplastic retinopathy.
Reference Age at
diagnosis Origin of cancer
Interval between diagnosis
of primary tumor and
onset of visual symptoms
(months)
Interval from visual
symptoms to death
(months)
[2] 62 Endometrioid sarcoma +5 7
[3]7 7 Poorly diﬀerentiated adenocarcinoma of
the ovary
−23 23
[4] 60 Papillary cystadenocarcinoma of ovary +7 NA
[5] 50 Uterine cancer +36 No information
[6]8 9 P o o r l y d i ﬀerentiated carcinoma of ovary −15 15
[7]6 1 Undiﬀerentiated neoplasm of the cervix
uteri
−72 0
[8]6 4 Undiﬀerentiated endometrial
adenocarcinoma
Initial diagnosis: +8
recurrence: −3 3
[9] 68 Carcinoma of the cervix −31 2
65 Serous cystadenocarcinoma of ovary +24 Well after 78 months
[10] 63 Clear cell carcinoma of ovary −58
[11] 72 Uterine small cell carcinoma −26
[12]6 5 Malignant mixed mullerian tumor
(homologous) of the endometrium
−1N A
[13] 77 Anaplastic uterine carcinoma +10 NA
[14] 60 Endometrial carcinoma Initial diagnosis: −3
recurrence: −11 27
[15] 67 Small-cell endometrial carcinoma +12 4
[16] 35 Carcinoid tumour of cervix Article in german
[17]6 0 Mixed-type small cell carcinoma of
endometrium
Initial diagnosis: −4
recurrence: −18 30
[18] 55 Clear cell carcinoma of ovary +27 4
[19]7 5 Poorly diﬀerentiated adenocarcinoma of
the ovary
−11
Not stated; patient
died after 6 courses of
chemotherapy
[1] 77 Adenocarcinoma cervix −0.5 –1 NA
[20]3 5 Serous ovarian cancer and endometrial
carcinoma
Initial diagnosis: +24
recurrence: +1 6
[21] 70 Uterine cancer +12 54
[22]5 8
Small cell undiﬀerentiated carcinoma
with minor components of endometroid
and mucinous grade 1/3 of the
endometrium
−12
[23] 57 Uterine small cell carcinoma −1.5 NA
[24] 66 Endometrial carcinoma +4 NA
[25] 67 Endometrial carcinoma Concomitant NA
[26] 68 Adenocarcinoma of cervix −48 NA
[27]7 0 Neuroendocrine carcinoma of fallopian
tube
−22 NA
Current 62 Clear cell carcinoma of the uterus +8 NA
The interval between diagnosis of the inciting tumor and the diagnosis of retinopathy is listed as positive numbers if the inciting tumor was diagnosedb e f o r e
the diagnosis of retinopathy and as negative numbers if the inciting tumor was diagnosed after the diagnosis of retinopathy.
NA: patient alive at the time of publication.
two occasions. Carboplatin and paclitaxel were both reduced
throughout the course of her treatment. Prior to her 4th
cycle, she began to complain about “dimmed vision”. CT
scans of her chest abdomen and pelvis were repeated at
that time. Her previously identiﬁed lymphadenopathy had
improved, and, due to her overall state, we decided to hold
any further chemotherapy. In order to investigate the visual
changes, a referral was made to a retinal specialist.Case Reports in Obstetrics and Gynecology 3
Ophthalmologic examination revealed best corrected
visual acuity of 20/150 in both eyes. Anterior segment
examination was unremarkable. Fundoscopy demonstrated
multiple conﬂuent oval hypopigmented patches at the
level of the retinal pigment epithelium (RPE) and a few
pigmented choroidal lesions in the posterior pole in both
eyes. Fluorescein angiography revealed areas of transmis-
sion hyperﬂuorescence, and optical coherence tomography
showed bilateral serous retinal detachment and areas of RPE
loss interspersed with zones of thickened RPE. A diagnosis of
cancer-associated nummular loss of the pigment epithelium
was made.
The patient was treated systemically with ﬁve sessions
of plasmapheresis and intravenous immunoglobulin, and
locally with bilateral subtenons triamcinolone acetonide
injection and an intravitreal triamcinolone acetonide injec-
tion in the left eye. Despite treatment, eight months after
presentation, vision deteriorated to light perception only
in both eyes. She was found to have further loss of RPE,
enlargement of one pigmented choroidal lesion, and persis-
tent retinal detachments. Twelve months after presentation
cataracts developed as well as iris-pigmented lesions.
Fivemonthsafterthecompletionofinitialchemotherapy
and after investigations and treatment for visual loss, the
patient underwent another staging CT scan. This scan
showed an increase in the size of the patient’s retroperitoneal
lymph nodes, and a ﬁne needle aspiration did conﬁrm recur-
rentmetastaticdisease13monthsaftertheinitialsurgerywas
performed. After consultation with medical oncology, it was
deemedthatshewouldnottolerateconventionalchemother-
apy nor was she a candidate for clinical trials. She was started
on Megace 80mg twice daily. Unfortunately, she continued
to show signs of progressive disease and 21 months after her
initial operation was discharged to hospice care.
3. Discussion
Bilateral diﬀuse uveal melanocytic proliferation (BDUMP)
is a rare paraneoplastic syndrome, characterized by bilat-
eral vision loss in patients with a systemic carcinoma
[24]. Our patient was diagnosed with a rare variant of
BDUMP, named cancer-associated nummular loss of the
retinal pigment epithelium. It is the only reported case of
clear cell adenocarcinoma of the uterus associated with a
paraneoplastic syndrome. BDUMP is characterized by uveal
tract thickening and degeneration and atrophy of the retinal
pigment epithelium [21] and usually does not respond to
corticosteroid treatments [24] as was the case with our
patient.
There were 28 previously reported cases of gynecologic
cancers associated with paraneoplastic retinopathy (Table 1).
Of these, 14 patients were diagnosed with endometrial
cancer, 7 with ovarian cancer, 5 with cervical cancer, 1 with
fallopian tube cancer, and 1 with concomitant endometrial
and ovarian cancers. The average age of patients at the time
of diagnosis was 64 years (range, 35–89 years). Information
regarding the interval from visual symptoms to time of death
is limited but can range from several months to several years.
Atthetimeofpublication,ourpatientisaliveinhospicecare,
16 months after her initial visual complaint, and 21 months
after her cancer diagnosis was made.
Paraneoplastic retinopathy has been related to other
cancer types, including lung and various GI malignancies
(bowel, gallbladder, pancreas). Typically, ocular manifes-
tations antedate symptoms of the underlying carcinoma
by 3–12 months [9, 21]. However, our patient and the
majority of gynecologic cases (15/28) have visual symptoms
following the diagnosis of cancer. Classically, patients com-
monly complain of ﬂickering lights, reduced visual acuity,
color impairment and photosensitivity [28]. Our patient
complained of “darkness” and visual “dimming.”
The onset of visual symptoms during treatment for
a gynecologic malignancy should alert the oncologist to
a possible cancer-associated retinopathy. A referral to the
ophthalmologist is warranted.
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